Structural Implications for Selective Targeting of PARPs
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that use NAD(+) as a substrate to synthesize polymers of ADP-ribose (PAR) as post-translational modifications of proteins. PARPs have important cellular roles that include preserving genomic integrity, telomere maintenance, transcriptional regulation, and cell fate determination. The diverse biological roles of PARPs have made them attractive therapeutic targets, which have fueled the pursuit of small molecule PARP inhibitors. The design of PARP inhibitors has matured over the past several years resulting in several lead candidates in clinical trials. PARP inhibitors are mainly used in clinical trials to treat cancer, particularly as sensitizing agents in combination with traditional chemotherapy to reduce side effects. An exciting aspect of PARP inhibitors is that they are also used to selectivity kill tumors with deficiencies in DNA repair proteins (e.g., BRCA1/2) through an approach termed "synthetic lethality." In the midst of the tremendous efforts that have brought PARP inhibitors to the forefront of modern chemotherapy, most clinically used PARP inhibitors bind to conserved regions that permits cross-selectivity with other PARPs containing homologous catalytic domains. Thus, the differences between therapeutic effects and adverse effects stemming from pan-PARP inhibition compared to selective inhibition are not well understood. In this review, we discuss current literature that has found ways to gain selectivity for one PARP over another. We furthermore provide insights into targeting other domains that make up PARPs, and how new classes of drugs that target these domains could provide a high degree of selectivity by affecting specific cellular functions. A clear understanding of the inhibition profiles of PARP inhibitors will not only enhance our understanding of the biology of individual PARPs, but may provide improved therapeutic options for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“In terms of therapeutic potential, PARP inhibitors are more effective at killing BRCA deficient cells than with PARP-1 knockdown (5, 6).”
Background(2023) · doi:10.1126/science · Cited by 6,063
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Colman (2022) · doi:10.1073/pnas · Cited by 4,370
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Cohen-Armon, M., Visochek, L., Rozensal, D., Kalal, A., Geistrikh, I., Klein, R., Bendetz-Nezer, S., Yao, Z., & Seger, R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.012 · Cited by 329
Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2
Oliver, A. W. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh215 · Cited by 127 · cited 2×
“The minor sequence variation, Glu763/Gln319 in HD helix αF, and the presence of Tyr539 of PARP-2 in the acceptor loop, have been noted as important differences in which selectivity could be achieved (22).”
Background
Cited by
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Gupte, R., Liu, Z., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.291518.116 · Cited by 681
“Historically, most PARPis are nicotinamide mimics that target the PARP NAD+-binding pocket (Steffen et al. 2013), making thembroadly effective against many PARPs.”
BackgroundPARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Family-wide analysis of poly(ADP-ribose) polymerase activity
Vyas, S., Matic, I., Uchima, L., Rood, J., Zaja, R., Hay, R. T., Ahel, I., & Chang, P. (2014) · Nature Communications · doi:10.1038/ncomms5426 · Cited by 497
Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins
Alemasova, E. E., & Lavrik, O. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz120 · Cited by 497
PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain
Dawicki-McKenna, J. M., Langelier, M.-F., DeNizio, J. E., Riccio, A. A., Cao, C. D., Karch, K. R., McCauley, M., Steffen, J. D., Black, B. E., & Pascal, J. M. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.013 · Cited by 340
Self-citation
Metadata
- Authors
- Steffen, J. D., Brody, J. R., Armen, R. S., & Pascal, J. M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 301-301
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2166571825
- Cited by
- 155
- References
- 8
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structural Implications for Selective Targeting of PARPs. https://app.cochat.ai/papers/10.3389/fonc.2013.00301
- The paper
- Steffen, J. D., Brody, J. R., Armen, R. S., & Pascal, J. M. (2013). Structural Implications for Selective Targeting of PARPs. Frontiers in Oncology. https://doi.org/10.3389/fonc.2013.00301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.